These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1828755)

  • 21. Inhibition of equine complement activity by polysulfated glycosaminoglycans.
    Rashmir-Raven AM; Coyne CP; Fenwick BW; Gaughan EM; Andrews GA; DeBowes RM
    Am J Vet Res; 1992 Jan; 53(1):87-90. PubMed ID: 1539920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-complement activity of oleanolic acid: an inhibitor of C3-convertase of the classical complement pathway.
    Kapil A; Sharma S
    J Pharm Pharmacol; 1994 Nov; 46(11):922-3. PubMed ID: 7897600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic inhibition of the early phase of complement activation.
    Roos A; Ramwadhdoebé TH; Nauta AJ; Hack CE; Daha MR
    Immunobiology; 2002 Sep; 205(4-5):595-609. PubMed ID: 12396018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in rats.
    Yeh CG; Marsh HC; Carson GR; Berman L; Concino MF; Scesney SM; Kuestner RE; Skibbens R; Donahue KA; Ip SH
    J Immunol; 1991 Jan; 146(1):250-6. PubMed ID: 1824590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-complement effects of lactoferrin-derived peptides.
    Samuelsen Ø; Haukland HH; Ulvatne H; Vorland LH
    FEMS Immunol Med Microbiol; 2004 Jun; 41(2):141-8. PubMed ID: 15145458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A peptide derived from the parasite receptor, complement C2 receptor inhibitor trispanning, suppresses immune complex-mediated inflammation in mice.
    Inal JM; Schneider B; Armanini M; Schifferli JA
    J Immunol; 2003 Apr; 170(8):4310-7. PubMed ID: 12682267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological manipulation of complement system.
    Asghar SS
    Pharmacol Rev; 1984 Dec; 36(4):223-44. PubMed ID: 6395140
    [No Abstract]   [Full Text] [Related]  

  • 28. Biological and immunological properties of Sugi basic protein-pullulan conjugate. II. Is the reduced ability to elicit the Arthus reaction based on the poor activation of complement by immune complex consisting of anti-Sugi basic protein and Sugi basic protein-pullulan?
    Usui M; Taniguchi Y; Ando S; Kurimoto M; Matuhasi T
    Int Arch Allergy Appl Immunol; 1990; 91(1):74-9. PubMed ID: 2138137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist.
    Strachan AJ; Shiels IA; Reid RC; Fairlie DP; Taylor SM
    Br J Pharmacol; 2001 Dec; 134(8):1778-86. PubMed ID: 11739255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The inhibitory effect of rosmarinic acid on complement involves the C5 convertase.
    Peake PW; Pussell BA; Martyn P; Timmermans V; Charlesworth JA
    Int J Immunopharmacol; 1991; 13(7):853-7. PubMed ID: 1761351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats.
    Strachan AJ; Woodruff TM; Haaima G; Fairlie DP; Taylor SM
    J Immunol; 2000 Jun; 164(12):6560-5. PubMed ID: 10843715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The classical and alternative pathways of complement activation play distinct roles in spontaneous C3 fragment deposition and membrane attack complex (MAC) formation on human B lymphocytes.
    Leslie RG; Nielsen CH
    Immunology; 2004 Jan; 111(1):86-90. PubMed ID: 14678202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for different requirements in physical state for the interaction of lipopolysaccharides with the classical and alternative pathways of complement.
    Wilson ME; Morrison DC
    Eur J Biochem; 1982 Nov; 128(1):137-41. PubMed ID: 6756918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complement mediated inflammatory reactions.
    Kunkel SL; Fantone JC; Ward PA
    Pathobiol Annu; 1981; 11():127-54. PubMed ID: 6173833
    [No Abstract]   [Full Text] [Related]  

  • 35. Accumulation of platelets at sites of antigen-antibody-mediated injury: a possible role for IgE antibody and mast cells.
    Kravis TC; Henson PM
    J Immunol; 1977 May; 118(5):1569-73. PubMed ID: 140191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of immunological adjuvants on the mouse complement system. I. The inability of the polyanion heparin to act as an adjuvant is paralleled by inefficient alternative complement pathway inhibition.
    Klerx JP; Van Dijk H; Damen H; Rademaker PM; Willers JM
    Int J Immunopharmacol; 1983; 5(6):549-53. PubMed ID: 6662600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of mouse complement activity by contaminants of technical grade pentachlorophenol.
    White KL; Anderson AC
    Agents Actions; 1985 Jul; 16(5):385-92. PubMed ID: 4050617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo.
    Moran P; Beasley H; Gorrell A; Martin E; Gribling P; Fuchs H; Gillett N; Burton LE; Caras IW
    J Immunol; 1992 Sep; 149(5):1736-43. PubMed ID: 1380537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complement-inhibiting cucurbitacin glycosides from Picria fel-terrae.
    Huang Y; De Bruyne T; Apers S; Ma Y; Claeys M; Vanden Berghe D; Pieters L; Vlietinck A
    J Nat Prod; 1998 Jun; 61(6):757-61. PubMed ID: 9644059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. STUDIES ON THE LOCALIZATION OF CIRCULATING ANTIGEN-ANTIBODY COMPLEXES AND OTHER MACROMOLECULES IN VESSELS. I. STRUCTURAL STUDIES.
    COCHRANE CG
    J Exp Med; 1963 Oct; 118(4):489-502. PubMed ID: 14067901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.